Waiving in vivo studies for monoclonal antibody biosimilar development: National and global challenges
Owner/Developer: Taylor & Francis Group
| Country: | United Kingdom |
|---|---|
| Languages: | English |
| Url: | http://www.tandfonline.com/doi/full/10.1080/19420862.2016.1145331 |
| Description: |
Biosimilars are biological medicinal products that contain a version of the active substance of an already authorised original biological medicinal product (the innovator or reference product). The first approved biosimilar medicines were small proteins, and more recently biosimilar versions of innovator monoclonal antibody (mAb) drugs have entered development as patents on these more complex proteins expire. In September 2013, the first biosimilar mAb, infliximab, was authorised in Europe. In March 2015, the first biosimilar (Zarxio™, filgrastim-sndz, Sandoz) was approved by the US Food and Drug Administration; however, to date no mAb biosimilars have been approved in the US. There are currently major differences between how biosimilars are regulated in different parts of the world, leading to substantial variability in the amount of in vivo nonclinical toxicity testing required to support clinical development and marketing of biosimilars. There are approximately 30 national and international guidelines on biosimilar development and this number is growing. The European Union's guidance describes an approach that enables biosimilars to enter clinical trials based on robust in vitro data alone; in contrast, the World Health Organization's guidance is interpreted globally to mean in vivo toxicity studies are mandatory. |
| Category: | Publication |
| Channel: | Website |
| Audience: | Scientists - Regulators - Industry - Researchers - Educators - Students |
| User access: | Open access |
| Updating frequency: | 2016 |
| Relevance: | Replacement - Reduction - Refinement |
| Purpose: | Documentation and information |
| Technology/Tools: | Alternative test methods (in vitro) - Animal testing (in vivo) |
Fant du det du lette etter?
Ja, jeg fant det! Nei, jeg fant det ikke!Takk for din tilbakemelding! Vær oppmerksom på at vi ikke kan kontakte deg hvis ikke du oppgir din epostadresse.
Hva lette du etter?
Gi oss gjerne en tilbakemelding slik at vi kan forbedre informasjonen på siden. På forhånd takk for hjelpen! Vennligst skriv inn din epostadresse hvis du vil ha et svar.
Kontakt oss gjerne på e-post hvis du har spørsmål.